<DOC>
	<DOCNO>NCT00857168</DOCNO>
	<brief_summary>Testosterone replacement treatment effective way treat hypogonadism men . Acrux propriety testosterone replacement product , Testosterone MD-Lotion study evaluate impact application antiperspirant deodorant absorption testosterone , apply pre-application Testosterone MD-Lotion® ( cutaneous solution ) . The study also aim evaluate impact wash application site absorption testosterone , wash post-application Testosterone MD-Lotion® ( cutaneous solution ) .</brief_summary>
	<brief_title>To Determine Effects Deodorant , Antiperspirant Washing Pharmacokinetics 2 % Testosterone MD Lotion</brief_title>
	<detailed_description />
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Healthy premenopausal female subject ≥18 ≤45 year age qualify general medical health . Disqualifying concurrent condition allergy/sensitivity testosterone replacement therapy .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>